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Purpose: To analyze the outcomes of thulium vapoenucleation of the prostate (ThuVEP) in the man-
agement of benign prostatic hyperplasia. The outcomes of this increasingly popular procedure are yet to
be conﬁrmed in patients with various prostate sizes and health status.
Materials and methods: Three hundred and three patients who underwent ThuVEP were included and
stratiﬁed in subgroups according to prostate size and age. We analyzed patient demographics, preop-
erative disease-related parameters, and perioperative and follow-up results. Correlation of prostate size
and operation time were also assessed.
Results: Baseline mean prostate volume was 61.0 mL (range 19.3e226 mL), mean urinary peak ﬂow rate
(Qmax) was 8.6 mL/second (range 1.4e23.25 mL/second), mean postvoid residual volume was 126.2 mL
(range 0e649 mL) and mean International Prostate Symptom Score was 25.1 (range 8e35). The mean
operation time was 84.0 minutes and 88.6 minutes for total and prostate volume >80 mL, respectively.
After laser surgery, there were mean reductions of 5.3 ng/mL, 7.5 ng/mL, 3.7 ng/mL, and 3.5 ng/mL (38.0%,
49.7%, 30.3%, and 36.5% change from baseline) in prostate-speciﬁc antigen level among the four groups.
As for postvoid residual volume, there was a signiﬁcant reduction in volume in the total, prostate volume
>80 mL and prostate volume <80 mL (73.9 mL, 70.8 mL, and 67 mL, respectively) but not in the
elderly group (31.4 mL, p ¼ 0.068). Similarly, Qmax improved signiﬁcantly in all (6.7 mL/second, 5.9 mL/
second, and 6.0 mL/second, respectively) except the elderly group (2.3 mL/second, p ¼ 0.103). The
operation time was highly correlated with the prostate size.
Conclusion: This study indicates that ThuVEP is an effective treatment option for benign prostatic
obstruction in patients with different prostate size and age. The technique allows an efﬁcient surgical
course with operation time highly correlated with prostate size.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Conventional transurethral resection of the prostate (TURP) has
been the standard treatment to alleviate bladder outlet obstruction
caused by benign prostate hyperplasia (BPH) for several decades
because of its established long-term efﬁcacy. However, the short-
term postsurgical morbidity usually imposes a signiﬁcant burden
and stress on this group of elderly patients.1ang Gung Memorial Hospital,
aoyuan 333, Taiwan.
ociation. Published by Elsevier Ta
, et al., Treatment outcomes
016), http://dx.doi.org/10.101Laser prostatectomy has been used in the treatment of symp-
tomatic BPH for nearly two decades. Promising results by using a
range of lasers with different wavelengths, absorption rate, power
capacities, and mode of action have been published. All of them
demonstrated similar postoperative outcomes to TURP, with fewer
complications and less blood loss. Although there are similarities
between laser wavelengths and surgical approaches, different tis-
sue interaction makes it necessary for surgeons to be aware of the
existing variations to safely use the laser to achieve the desired
outcomes. In principle, laser beams with low tissue absorption
coefﬁcient penetrate deeper, whereas a high absorption coefﬁcient
offers shallow penetration.
Among all the emerging laser techniques, the introduction of
thulium vapoenucleation of the prostate (ThuVEP) has gained highiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
of benign prostate hyperplasia by thulium vapoenucleation of the
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Table 1
Baseline characteristics, stratiﬁed by prostate size and age.
Characteristics Total TRUS >80 mL TRUS <80 mL Age >80 y
Patient, n (%) 303 (100.0) 121 (39.9) 182 (60.1) 38 (12.5)
Age (y),
mean (SD) 70.1 (7.9) 70.5 (7.9) 69.8 (7.9) 82.8 (2.4)**
PSA (ng/mL)
Mean (SD) 9.1 (12.2) 10.8 (13.9) 8.0 (8.6)* 8.4 (6.1)
Range 0.34e106.53 0.34e106.53 0.58e95.5 1.1e29.4
TRUS (mL)
Mean (SD) 61.0 (28.8) 106.4 (28.2) 51.8 (15.1)** 67.2 (27.8)
Range 19.3e226 80.9e226 19.3e79.7 26.4e123.9
Qmax (mL/s)
Mean (SD) 8.6 (4.3) 8.5 (4.4) 8.6 (4.3) 8.6 (4.3)
Range 1.4e23.2 2.0e20.0 1.4e23.2 2.0e22.0
PVR (mL)
Mean (SD) 126.2 (131.6) 119.8 (117.0) 130.0 (140.0) 123.8 (134.4)
Range 0e649 0e506 0e649 5e540
IPSS
Mean (SD) 25.1 (4.7) 24.9 (5.2) 25.1 (4.7) 24.9 (5.0)
Range 8e35 8e34 10e35 17e34
*Signiﬁcant difference in PSA, p ¼ 0.031 between TRUS >80 mL versus TRUS <80 mL
group.
**Signiﬁcant difference in TRUS volume, p < 0.001 between TRUS >80 mL versus
TRUS <80 mL group; signiﬁcant difference in age, p < 0.001 between age >80 years
versus total.
IPSS ¼ International Prostate Symptom Score; PSA ¼ prostate-speciﬁc antigen;
PVR ¼ postvoid residual volume; Qmax ¼ urinary peak ﬂow rate; SD ¼ standard
deviation; TRUS ¼ transrectal ultrasound.
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Thulium is a metal that serves as the medium to emit a laser with a
wavelength of 2013 nm, allowing it to match with the 1920 nm
water absorption peak in tissue. Its high absorption coefﬁcient re-
sults in shallow penetration of <0.4 mm that offers more precise
incision ability to minimize deep tissue and nerve damage. With
less heat release than other lasers, it has the advantage of rapid
vaporization and coagulation. On top of these advances, enucle-
ation makes rapid removal of the vast majority of the adenomas
possible with minimal regrowth expected. Additionally, enucle-
ation can reserve incised tissue for pathological testing.
After the introduction of various endoscopic laser techniques in
our center since early 2000, Lee et al2 published the results of 245
patients receiving thulium laser, and the functional outcomes were
excellent with a low rate of postoperative complications. Currently,
an increasing number of patients with different health background
and disease status have been accumulated. We revisited the patient
data and stratiﬁed them into subgroups for further in-depth anal-
ysis of the outcome of this technique in the alleviation of BPH
symptoms, to generate an updated reference and evidence-based
information for the evolving techniques.
2. Materials and methods
Between August 2006 and April 2015, data were collected and
analyzed fromall patientswhounderwent ThuVEP in a single center
in Taiwan. The chart numbers of patients who underwent ThuVEP
were retrospectively extracted from the institutemedical records by
linking the International Classiﬁcation of Diseases (ICD) codes with
the procedure codes. The associated clinical, laboratory, disease
status and perioperative information of each chart number were
then reviewedmanually. Patients who had baseline data missing or
conﬁrmed diagnosis of cancer were subsequently excluded.
Baseline clinical and laboratory characteristics included pa-
tients' age, prostate-speciﬁc antigen (PSA) level, prostate size as
measured by transurethral ultrasound (TRUS), urinary peak ﬂow
rate (Qmax), postvoid residual urine volume (PVR), and Interna-
tional Prostate Symptom Score (IPSS) were collected.
The ThuVEP procedures were performed by a single experienced
urology surgeon. Using 2-mm continuous wave emitting end-ﬁring
ﬁbers, the procedurewas carried out as described previously.3 After
the resectoscope was placed in the urethra at the distal resection
border close to the prostatic apex, careful mechanical incisions
from the bladder neck were carried out at 5 o'clock and 7 o'clock
directions toward the verumontanum. A third incision was then
made from the bladder neck to the level of verumontanum in the 12
o'clock direction, and the separated median lobe was enucleated.
Bymoving clockwise for the right lateral lobe and counterclockwise
for the left lateral lobe, the two lateral lobes were similarly
enucleated along the capsule. The enucleated tissues were ﬂipped
toward the bladder. The adenomas were morcellated with a me-
chanical tissue morcellator and removed from the bladder for
routine pathological examination. Residual apical tissue was
vaporized as needed using the vaporizing mode. At the end of the
procedures, a urethral catheter was routinely inserted into the
bladder and irrigation started with normal saline until hematuria
subsided. Patients were discharged after conﬁrming that bleeding
had subsided and voiding pattern returned to normal after removal
of the catheter.
Perioperative parameters including operation time, and post-
operative PSA, Qmax, PVR, and IPSS were collected accordingly. The
records within 3 months after surgery and the latest record were
used for outcome analysis. However, the postoperative TRUS and
IPSS data for most patients were missing as these were not
mandatory measurements in normal practice.Please cite this article in press as: Hou C-M, et al., Treatment outcomes
prostate in aging men, Urological Science (2016), http://dx.doi.org/10.101The data are presented as mean ± standard deviation, range,
absolute change, and percentage change from baseline. All analyses
were performedwith a commercial statistical calculator. Two-sided
p < 0.05 was regarded as statistically signiﬁcant. Analysis of vari-
ance was used to compare subgroup data sets. One sample t test
was used for pre- and postoperative comparison. A correlation
coefﬁcient was calculated to check the correlation between TRUS
volume and operation time.3. Results
From the overall cohort of 309 patient records, 303 records of
patients with symptomatic BPH who underwent ThuVEP were
retrieved after excluding six cases with conﬁrmed diagnosis of
prostate cancer. Among them, 121 patients had a prostate size
>80 mL as measured by TRUS. Thrity-eight patients (12.5%) were
aged >80 years at the time of surgery.
The baseline characteristics of all study patients and subgroups
are shown in Table 1. The mean age (70.1 y) and mean prostate size
(61.0 mL) of our study cohort were similar to those reported in
previous studies, but the Qmax, PVR, and IPSS varied widely among
different study groups.4,5
Between the TRUS >80 mL and TRUS <80 mL subgroups, there
was a signiﬁcant difference in PSA level (10.8 vs. 8.0 ng/mL,
p ¼ 0.031) but no signiﬁcant difference in Qmax, PVR or IPSS at
baseline between the groups. Patients with larger prostate size did
not seem to have more serious obstructive symptoms and greater
urine retention than patients with smaller prostate.
As for the elderly subgroup (>80 y), all the baseline parameters,
including PSA level, Qmax, PVR, and IPSS did not differ signiﬁcantly
with the overall patient population.
The perioperative and follow-up data are depicted in Table 2.
Among the four groups, the operation time was signiﬁcantly longer
in the TRUS >80 mL group compared to the TRUS <80 mL group
(88.6 min vs. 80.9 min, p ¼ 0.018).
The decrease in PSA level from baseline in all four groups (Total,
TRUS >80 mL, TRUS <80 mL and age >80 y) was signiﬁcantof benign prostate hyperplasia by thulium vapoenucleation of the
6/j.urols.2016.03.006
Table 2
Perioperative and follow-up data, stratiﬁed by prostate size and age.
Characteristics Total TRUS >80 mL TRUS <80 mL Age >80 y
Operation time (min)
Mean (SD) 84.0 (33.3) 88.6 (27.9) 80.9 (27.3)* 84.7 (32.3)
Range 25e248 29e195
PSA (ng/mL)
Mean (SD) 4.4 (4.6) 4.3 (4.8) 4.5 (4.2) 4.4 (4.5)
Change (%) 5.3 (38.1)** 7.5 (49.7)** 3.7 (30.3)** 3.5 (36.5)**
Qmax (mL/s)
Mean (SD) 14.2 (7.9) 14.0 (7.2) 14.3 (7.8) 11.2 (5.3)
Change (%) 6.7 (110.3)** 5.9 (114.7)** 6.0 (99.4)** 2.3 (67.7)#
PVR (mL)
Mean (SD) 54.8 (53.7) 56.7 (50.9) 53.6 (52.1) 82.6 (60.7)
Change (%) 73.9 (19)** 70.8 (26)** 67.0 (27.3)** 31.4 (180.6)##
*Signiﬁcant difference, p ¼ 0.018, between TRUS >80 mL versus <80 mL.
**Signiﬁcant difference, p < 0.001, change from baseline.
#No signiﬁcant difference, p ¼ 0.103 change from baseline.
##No signiﬁcant difference, p ¼ 0.068 change from baseline.
PSA ¼ prostate-speciﬁc antigen; PVR ¼ postvoid residual volume; Qmax ¼ urinary peak ﬂow rate; SD ¼ standard deviation; TRUS ¼ transrectal ultrasound.
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tively; all p < 0.001). Further subgroup analysis of the changes
between the TRUS >80 mL and TRUS <80 mL groups did not reveal
any signiﬁcant difference in the magnitude of change.
The improvement in Qmax in the three groups (Total, TRUS
>80 mL and TRUS <80 mL) also showed signiﬁcant differences
(6.7 mL/s, 5.9 mL/s, and 6.0 mL/s, respectively; all p < 0.001).
However the increase in mean Q max in the elderly group (age
>80 y) of 2.3 mL/second did not reach statistical signiﬁcance from
baseline (p ¼ 0.103).
Similarly, the reduction in PVR volume in the three groups
(Total, TRUS >80 mL and TRUS <80 mL) also showed signiﬁcant
differences (73.9 mL, 70.8, and 67 mL, respectively; all
p < 0.001). However, the decrease in PVR in the elderly group (age
>80 y) was lower (31.4 mL), with no signiﬁcant difference from
baseline (p ¼ 0.068).
In general, there was no prostate capsule perforation reported
and none of the patients reported bladder wall injury during
morcellation. Recatheterization and blood transfusion were not
required in almost all the cases after laser procedures.
The correlation between prostate size and operation time is
presented in Figure 1. After stratifying the patients according to
TRUS volume (10-mL intervals), operation time correlated signiﬁ-
cantly with TRUS volume (r ¼ 0.974). In general, the operation time
was around 1 hour in patients with prostate size <40 mL, 90 mi-
nutes for those <80 mL, and2 hours were needed to complete the
procedure for those with prostate size >100 mL.Figure 1. Prostate size ve
Please cite this article in press as: Hou C-M, et al., Treatment outcomes
prostate in aging men, Urological Science (2016), http://dx.doi.org/10.1014. Discussion
Ever since the ﬁrst successful results reported by Bach et al6 in
54 patients receiving thulium vaporesection (ThuVaRP) in 2007, a
series of studies were published by the same German group,
providing information of intermediate-term follow-up,7 using
different energy units and different size of prostates.8e10 In general,
there was no major clinical meaningful differences in these study
reports regarding effectiveness.
The thulium:yttriumealuminumegarnet laser has four appli-
cation modes: vaporization, vaporesection, ThuVEP, or enucleation.
The availability of higher energy output satisﬁes the different needs
during the course of removal of the adenomas, thus improving the
efﬁciency of the procedure. In the last few years, holmium laser
enucleation has the greatest number of well-controlled study re-
sults for prostatectomy among different lasers and was proposed as
the new gold standard in 2013.11 Unlike pulsed holmium laser,
thulium laser is a continuous wave laser that produces faster cuts
during prostatectomy. Thulium laser ﬁber equipped with 150 W
2 mm thulium:yttriumealuminumegarnet can perform vapor-
ization and resection or enucleation modes in prostatectomy.
Not surprisingly, from our study results, a promising functional
outcome improvement was seen across all the patient subgroups.
Theoretically, a larger volume of prostate tissue should have been
removed in the large prostate group, as reﬂected in the greater
reduction in PSA level in the TRUS >80 mL group (7.5 ng/mL
vs.3.7 ng/mL versus the TRUS<80mL group). However, this did notrsus operation time.
of benign prostate hyperplasia by thulium vapoenucleation of the
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and PVR. No signiﬁcant difference was observed between the two
groups. It seems that the evaluation of postoperative functional
improvement may be unavoidably confounded by the subjective
patient-reported outcomes.
Important concerns for TURP are intraoperative bleeding and the
need for blood transfusion. Laser techniques greatly alleviate these
concerns, Shao et al12 and Zhang et al13 have reported less blood loss
by thulium than holmium laser enucleation of the prostate.
The risk of blood loss is higher in selected patients on antico-
agulants and antiplatelet agents. Anticoagulant users who received
TURP were associated with signiﬁcantly longer hospitalization and
higher rate of bladder clots, blood transfusions, prolonged hema-
turia, and thromboembolic events, even after anticoagulants had
been discontinued at the time of surgery.14 In this regard, Netsch
et al15 demonstrated that ThuVEP could be a safe and efﬁcacious
alternative for the treatment of symptomatic BPH in patients in
whom continuous oral anticoagulants are recommended.
In our patient cohort, aside from the previous report of relatively
low rate of intraoperative complications by our colleagues,2 our
elderly subgroup conﬁrmed the safety of this laser technique
through the normal operation length and uneventful perioperative
results. Although the procedures were demonstrated to be safe in
elderly people, the postoperative improvement in urination func-
tion tends to be less signiﬁcant in this group, which may have been
due to other coexisting health problems in the aging process.
TURP is more difﬁcult in patients with a large prostatic adenoma.
Large prostates >80 mL may need two stages of resection. Intra-
vasation of hypotonic ﬂuid and risk of Transurethral resection (TUR)
syndrome is high in large prostates. Our results have been encour-
aging with a short mean procedure time of 84 minutes in the overall
patient cohort and 88.6 minutes in patients with a large prostate,
which is comparable with Bach et al7,10 who reported a mean oper-
ation time of 72 minutes in the general patient pool and 100.3 mi-
nutes in a group of patients with prostate size >80 mL by using
ThuVEP. Further stratiﬁcation of our patient cohort according to
prostate size showed that the larger the prostate, the longer the
operation time required. This might help to provide information
regarding the expected operation time based on the size of the
prostate when this laser technique is chosen.
Generally speaking, TURP is a difﬁcult procedure to master and
requires a signiﬁcant learning curve. Thulium has a shorter learning
curve, and ThuVEP can be performed by surgeons with reasonable
operation efﬁciency only after 8e16 procedures.16
By using GreenLight laser (532 nm wavelength) with tissue
penetration of 0.8 mm, photoselective vaporization of prostate has
been limited to small to medium size prostate at the initial stage
and requires a gradual learning curve, starting from vaporization,
partial enucleation, and progression to entire adenoma enucle-
ation. Removal of a large prostate was only attempted after a
reﬁned technique of GreenLight photoselective en bloc enucleation
was proposed.17
The data from our study are consistent with most of the recent
reported results that demonstrate a signiﬁcant improvement in uri-
nary ﬂow and reduced postvoid urinary retention following ThuVEP.
In addition, patients with removal of a large prostate demonstrated
similar functional improvement as those with smaller prostates.Please cite this article in press as: Hou C-M, et al., Treatment outcomes
prostate in aging men, Urological Science (2016), http://dx.doi.org/10.101It should be noted that the retrospective nature of our study
lowered the level of evidence-based medicine. Despite this limi-
tation, our data reinforce the current existing knowledge and add to
what is already known about thulium lasers.
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